These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 28719017)
21. Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity. Zhou J; Ji M; Yao H; Cao R; Zhao H; Wang X; Chen X; Xu B Org Biomol Chem; 2018 May; 16(17):3189-3202. PubMed ID: 29648554 [TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, biological evaluation and molecular docking study of novel urea-based benzamide derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Lu G; Nie W; Xin M; Meng Y; Gu J; Miao H; Cheng X; Chan ASC; Zou Y Eur J Med Chem; 2022 Dec; 243():114790. PubMed ID: 36183505 [TBL] [Abstract][Full Text] [Related]
23. Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2. Yu J; Luo L; Hu T; Cui Y; Sun X; Gou W; Hou W; Li Y; Sun T Eur J Med Chem; 2022 Jan; 227():113898. PubMed ID: 34656898 [TBL] [Abstract][Full Text] [Related]
24. In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors. Salmas RE; Unlu A; Yurtsever M; Noskov SY; Durdagi S J Enzyme Inhib Med Chem; 2016; 31(1):112-20. PubMed ID: 26083304 [TBL] [Abstract][Full Text] [Related]
25. Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity. Velagapudi UK; Langelier MF; Delgado-Martin C; Diolaiti ME; Bakker S; Ashworth A; Patel BA; Shao X; Pascal JM; Talele TT J Med Chem; 2019 Jun; 62(11):5330-5357. PubMed ID: 31042381 [TBL] [Abstract][Full Text] [Related]
26. Synthesis of disaccharide nucleoside analogues as potential poly(ADP-ribose) polymerase-1 inhibitors. Zheng M; Mex M; Götz KH; Marx A Org Biomol Chem; 2018 Nov; 16(46):8904-8907. PubMed ID: 30203829 [TBL] [Abstract][Full Text] [Related]
27. A Simple, Sensitive, and Generalizable Plate Assay for Screening PARP Inhibitors. Kirby IT; Morgan RK; Cohen MS Methods Mol Biol; 2018; 1813():245-252. PubMed ID: 30097873 [TBL] [Abstract][Full Text] [Related]
28. Sirtuins are Unaffected by PARP Inhibitors Containing Planar Nicotinamide Bioisosteres. Ekblad T; Schüler H Chem Biol Drug Des; 2016 Mar; 87(3):478-82. PubMed ID: 26518726 [TBL] [Abstract][Full Text] [Related]
29. High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders. Peng X; Li Y; Qu J; Jiang L; Wu K; Liu D; Chen Y; Peng J; Guo Y; Cao X Eur J Med Chem; 2024 May; 271():116405. PubMed ID: 38678823 [TBL] [Abstract][Full Text] [Related]
30. Probing PARP1-inhibitor complexes for the development of novel inhibitors. Saqib U; Baig MS Cell Mol Biol (Noisy-le-grand); 2014 Oct; 60(3):43-52. PubMed ID: 25346248 [TBL] [Abstract][Full Text] [Related]
31. Design and synthesis of novel phthalazinone derivatives as potent poly(ADP-ribose)polymerase 1 inhibitors. Xin M; Sun J; Huang W; Tang F; Liu Z; Jin Q; Wang J Future Med Chem; 2020 Oct; 12(19):1691-1707. PubMed ID: 33012191 [No Abstract] [Full Text] [Related]
32. Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor. Wang B; Qian H; Yiu SM; Sun J; Zhu G Eur J Med Chem; 2014 Jan; 71():366-73. PubMed ID: 24361480 [TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors. Tian Y; Xie Z; Liao C Bioorg Med Chem Lett; 2020 Apr; 30(8):127036. PubMed ID: 32088129 [TBL] [Abstract][Full Text] [Related]
34. Cytotoxicity and cell death mechanisms induced by a novel bisnaphthalimidopropyl derivative against the NCI-H460 non-small lung cancer cell line. Lima RT; Barron GA; Grabowska JA; Bermano G; Kaur S; Roy N; Vasconcelos MH; Lin PK Anticancer Agents Med Chem; 2013 Mar; 13(3):414-21. PubMed ID: 23092269 [TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and evaluation of potential inhibitors for poly(ADP-ribose) polymerase members 1 and 14. Kam CM; Tauber AL; Levonis SM; Schweiker SS Future Med Chem; 2020 Dec; 12(24):2179-2190. PubMed ID: 33225736 [TBL] [Abstract][Full Text] [Related]
36. Recent Progress in the Research on Benzimidazole PARP-1 Inhibitors. Wu K; Chen M; Peng X; Li Y; Tang G; Peng J; Cao X Mini Rev Med Chem; 2022; 22(19):2438-2462. PubMed ID: 35319364 [TBL] [Abstract][Full Text] [Related]
37. PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling. van Beek L; McClay É; Patel S; Schimpl M; Spagnolo L; Maia de Oliveira T Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066057 [TBL] [Abstract][Full Text] [Related]
38. Synthesis and evaluation of novel benzimidazole derivatives as sirtuin inhibitors with antitumor activities. Yoon YK; Ali MA; Wei AC; Choon TS; Osman H; Parang K; Shirazi AN Bioorg Med Chem; 2014 Jan; 22(2):703-10. PubMed ID: 24387981 [TBL] [Abstract][Full Text] [Related]
39. A novel and orally active poly(ADP-ribose) polymerase inhibitor, KR-33889 [2-[methoxycarbonyl(4-methoxyphenyl) methylsulfanyl]-1H-benzimidazole-4-carboxylic acid amide], attenuates injury in in vitro model of cell death and in vivo model of cardiac ischemia. Oh KS; Lee S; Yi KY; Seo HW; Koo HN; Lee BH J Pharmacol Exp Ther; 2009 Jan; 328(1):10-8. PubMed ID: 18836068 [TBL] [Abstract][Full Text] [Related]